ENvue Medical Announces 40th U.S. Hospital Customer with Addition of a Virginia Medical Center Affiliated with the Mayo Clinic Care Network
Rhea-AI Summary
ENvue Medical (NASDAQ: FEED) announced a Virginia 255-bed nonprofit medical center affiliated with the Mayo Clinic Care Network adopted the ENvue™ Navigation Platform, marking ENvue's 40th U.S. hospital customer.
The hospital shifted feeding tube placement from interventional radiology to a nursing-led bedside model using ENvue's FDA 510(k)-cleared electromagnetic navigation for real-time visualization.
Positive
- None.
Negative
- None.
News Market Reaction – FEED
In the Apr 20 session, FEED declined 4.43%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -11.9% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 16 | Corporate update letter | Positive | -7.5% | Outlined 2025 progress and 2026 priorities including 39 U.S. hospitals. |
| Mar 24 | Hospital footprint growth | Positive | +58.0% | Expanded U.S. footprint to 39 hospitals via major Michigan health system. |
| Feb 24 | Patent allowance | Positive | +5.6% | USPTO Notice of Allowance for feeding tube with EM sensor and camera. |
| Jan 28 | Distribution partnership | Positive | +119.0% | Nationwide U-Deliver deal for OTC reusable ENFit syringe distribution. |
| Jan 21 | Executive appointment | Positive | +2.4% | Hired VP Commercial to drive U.S. commercialization and hospital expansion. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive news has more often aligned with strong upside moves, though one broad corporate update saw a negative reaction, indicating mixed but generally favorable responsiveness to milestones.
Over the past few months, ENvue has reported several commercial and strategic milestones. In January 2026, the company expanded its leadership team and signed a U.S. distribution partnership for reusable ENFit syringes, with that agreement coinciding with a 119.05% move. Subsequent patent progress on Feb 24, 2026 and a major Michigan health system win expanding to 39 hospitals were followed by positive price reactions. A broader stockholder letter on April 16, 2026 saw a -7.51% move, showing that investors have reacted more strongly to concrete commercial wins than to general updates.
Key Terms
interventional radiology medical
enteral care medical
gastrointestinal tract medical
510(k) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Regional hospital transitions feeding tube procedures from interventional radiology to bedside nursing care using the ENvue™ Navigation Platform
TYLER, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced that a Virginia-based, 255-bed nonprofit regional medical center affiliated with the Mayo Clinic Care Network is now using the ENvue™ Navigation Platform. The hospital is now performing feeding tube placement through a nursing-led bedside model, transitioning procedures from interventional radiology to trained clinical staff at the point of care.
“The transition to a nursing-led bedside model reflects a growing focus on efficiency and patient-centered care across hospital systems,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “With ENvue, care teams can perform feeding tube placement at the bedside, shifting procedures from interventional radiology to trained nursing staff and supporting a more streamlined process that reduces reliance on resource-intensive departments while maintaining clinical precision.”
The agreement marks ENvue’s 40th U.S. hospital customer. The Virginia-based medical center, serving more than 300,000 people, expands ENvue’s presence across regional health systems.
“We’re seeing growing demand for technologies that bring greater visibility and consistency to feeding tube placement,” said Marc Waldman, Vice President of Commercial at ENvue Medical. “Hospitals are looking for solutions that can be implemented across care teams, and we believe that real-time visualization helps support more standardized practices throughout the hospital.”
The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com
